Clinical Trial

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Study acronym: IZAR-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Protocol Amendment History 2 changes
notable Trial sites expanded: 139 -> 142 locations 2026-08-13
notable Trial sites expanded: 128 -> 135 locations 2026-04-30
Trial Details
NCT Number NCT06641089
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Arthritis, Psoriatic
Enrollment 600 participants
Start Date 2024-10-15
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12